세계의 mRNA 백신 및 치료제 시장 : 용도 분야별, 적응 질환별, 지역별-업계 동향 및 예측(-2035년)

mRNA Vaccine and Therapeutics Market by Application Area, Target Disease Indication and Geographical Regions : Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,943,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,126,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,335,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 26,042,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 mRNA 백신 및 치료제 시장 규모는 주로 감염증 치료를 목적으로 하는 mRNA 백신 및 치료제의 승인이 예상됨에 따라 2035년까지 19억 9,000만 달러 규모에 이를 것으로 예측됩니다.

메신저 리보 핵산(mRNA)은 단일 가닥 리보 핵산(RNA)의 일종이며 단백질 생산을 위한 유전 정보 전달에 중요한 역할을합니다. mRNA는 DNA 가닥에서 리보솜으로 단백질 합성을 위한 코딩 명령어를 운반하며, 이러한 명령어가 번역되어 기능적 단백질로 처리됩니다.

최근 몇 년동안 mRNA 기술은 다양한 질병과 장애를 예방하고 치료하기 위한 제약 업계에 혁명을 가져 왔습니다. 코로나19 백신의 성공은 mRNA 백신과 치료제의 길을 열었습니다. 지난 몇 년간 mRNA 백신 및 치료제과 관련된 170개 이상의 임상시험이 등록된 것은 주목할 만합니다. 여러 전임상 및 임상 연구가 이러한 플랫폼의 유효성을 보여주고 있으며, 지난 2년간 다양한 연구 논문이 발표되었습니다. 이는 이해관계자가 이 영역에서 광범위한 개발 노력을 하고 있음을 보여줍니다. 현재 45개 이상의 업계 관계자들이 폭넓은 적응증의 mRNA 의약품 후보 개발에 힘쓰고 있습니다.

COVID-19 백신의 성공, 연구 활동의 활성화, mRNA 의약품 후보의 풍부한 파이프라인은 향후 10년간 세계의 mRNA 백신 및 치료제 시장을 견인할 가능성이 높다고 보여지고 있습니다.

이 보고서는 세계의 mRNA 백신 및 치료제 시장에 대해 조사했으며, 시장 개요와 함께 용도 분야별, 적응 질환별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 서문

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려 사항

제4장 주요 요약

제5장 서문

제6장 시장 상황

제7장 경쟁 구도

제8장 기업 경쟁력 분석

제8장 유럽에 본사를 둔 mRNA 백신 및 치료제 개발자

제8장 아시아태평양 및 기타 지역에 본사를 둔 mRNA 백신 및 치료제 개발자

제9장 기업 프로파일

제10장 대기업 제약회사의 대처

제11장 스타트업의 건강 지표

제12장 임상시험 분석

제13장 파트너십 및 협업

제14장 자금 조달 및 투자 분석

제15장 특허 분석

제16장 시장 영향 분석 : 촉진요인, 억제요인, 기회, 과제

제17장 세계의 mRNA 백신 및 치료제 시장

제18장 mRNA 백신 및 치료제 시장 : 용도 분야별

제19장 mRNA 백신 및 치료제 시장 : 적응 질환별

제20장 mRNA 백신 및 치료제 시장 : 지역별

제21장 결론

제22장 주요 인사이트

제23장 부록 1 : 표 형식의 데이터

제24장 부록 2 : 기업 및 단체 일람

AJY

영문 목차

영문목차

MRNA VACCINE AND THERAPEUTICS MARKET: OVERVIEW

As per Roots Analysis, the global mRNA vaccine and therapeutics market is estimated to be worth USD 1.99 billion by 2035, primarily driven by the anticipated approval of mRNA vaccines and therapeutics intended for the treatment of infectious diseases.

The market sizing and opportunity analysis has been segmented across the following parameters:

Application Area

• COVID-19
• Other Indications

Target Disease Indication

• Influenza
• Respiratory Syncytial Virus Infection
• Cytomegalovirus Diseases

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Latin America
• Rest of the World

MRNA VACCINE AND THERAPEUTICS MARKET: GROWTH AND TRENDS

Messenger ribonucleic acid (mRNA) is a form of single-stranded ribonucleic acid (RNA) that is crucial role in transferring genetic information for protein production. The mRNA carries the coding instructions for protein synthesis from a DNA strand to the ribosomes, where these instructions are translated and processed into functional proteins.

In recent years, mRNA technology has revolutionized the pharmaceutical industry to prevent and treat a wide array of diseases and disorders. The success of COVID-19 vaccines has paved the path for mRNA vaccines and therapeutics. It is worth highlighting that, in the past few years, more than 170 clinical trials related to mRNA-based therapeutics / vaccines have been registered. Multiple preclinical and clinical studies show the efficacy of these platforms which have been published in the last two years across different research articles. This demonstrates the extensive development efforts being undertaken by stakeholders in this domain. At present, over 45 industry players are engaged in the development of mRNA drug candidates for a wide range of disease indications.

The success of COVID-19 vaccines, growing research activity and the rich pipeline of mRNA drug candidates is likely to drive the global mRNA vaccine and therapeutics market in the coming decade.

MRNA VACCINE AND THERAPEUTICS MARKET: KEY INSIGHTS

The report delves into the current state of the mRNA vaccine and therapeutics market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Presently, over 235 mRNA drug candidates are available in the market or under development; majority of these drug candidates are vaccines using lipid nanoparticles as delivery systems.

2. The pipeline features several drugs, which are being investigated across different phases of development; 60% of the drug candidates are designed to be administered via intramuscular routes.

3. The current market landscape of mRNA vaccine and therapeutics developers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US.

4. Stakeholders are actively upgrading their existing capabilities to further enhance their respective product pipeline and comply with the evolving industry benchmarks.

5. The growing interest of stakeholders is evident from the surge in partnership activity; clinical trial agreements emerged as the most prevalent partnership model adopted by drug developers.

6. Several investors, having realized the opportunity within this upcoming segment, have invested over USD 11 billion across various funding rounds.

7. More than 345,000 patients have been recruited / enrolled in clinical trials registered for various mRNA-based therapies, across different geographies.

8. Over 430 patents related to mRNA vaccine and therapeutics have been filed / granted by industry and non-industry stakeholders, indicating the growing intellectual capital in this domain.

9. Big pharma players have undertaken several initiatives, ranging from proprietary product development to strategic investments, to tap the lucrative opportunity in this rapidly growing market.

10. The projected opportunity for mRNA vaccine and therapeutics market is likely to be driven by the increasing research and development for mRNA-based drugs focused on non-COVID indications.

MRNA VACCINE AND THERAPEUTICS MARKET: KEY SEGMENTS

Several indications, such as Influenza, Respiratory Syncytial Virus, Cytomegalovirus, are the Expected to Drive the mRNA Vaccine and Therapeutics Market

Based on the application area, the market is segmented into COVID-19 and other indications. Owing to their proven efficacy against the COVID-19 infection, the vaccines and therapeutics developed for COVID-19 infection have captured the majority of the market share. However, the anticipated approval of mRNA vaccines for other indications is likely to drive the market in the coming decade.

Currently, Influenza Segment Occupies the Largest Share of the mRNA Vaccine and Therapeutics Market

Based on the target disease indication, the market is segmented into influenza, respiratory syncytial virus infection and cytomegalovirus diseases. It is worth highlighting that the vaccines and therapeutics developed for influenza are likely to drive the market in the coming decade. This can be attributed to the rise in investment in the research and development of influenza vaccines, along with growing awareness among governments and non-profit organizations about the importance of influenza prevention and control.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America and Rest of the World. It is worth highlighting that the market for North America holds the maximum share of the mRNA vaccines and therapeutics market. This trend is likely to remain the same in the coming decade.

Example Players in the mRNA Vaccine and Therapeutics Market

• Arcturus Therapeutics
• BioNTech
• CureVac
• Ethris
• IMMORNA
• Moderna
• Providence Therapeutics
• RNACure
• Suzhou Abogen Biosciences
• Turn Biotechnologies
• Gennova
• Innovac Therapeutics
• Kernal Biologics
• Pantherna Therapeutics
• pHion Therapeutics
• Recode Therapeutics
• Rejuvenation Technologies
• RNAimmune
• Strand Therapeutics
• Walvax
• Ziphius Vaccines

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Business Development Manager, Canvax
• Senior Director, Business Development, eTheRNA
• Team Leader, GC Biopharma

MRNA VACCINE AND THERAPEUTICS MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the mRNA vaccine and therapeutics market, focusing on key market segments, including [A] application area, [B] target disease indication and [C] key geographical regions.
• Market Landscape (Drug Therapies): A comprehensive evaluation of mRNA therapeutics and vaccines, considering various parameters, such as [A] phase of development, [B] type of drug candidate, [C] therapeutic area, [D] type of delivery system, [E] type of molecule encoded and [F] route of administration.
• Market Landscape (Drug Developers): A comprehensive evaluation of companies involved in the development of mRNA vaccine and therapeutics, considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] regional landscape and [E] key players engaged in this domain.
• Company Competitiveness Analysis: A comprehensive competitive analysis of mRNA vaccine and therapeutic developers, examining factors such as [A] developer strength, [B] pipeline strength and [C] number of therapeutic areas targeted.
• Company Profiles: In-depth profiles of key industry players engaged in the development of mRNA vaccine and therapeutics, focusing on [A] company overviews, [B] financial information, [C] mRNA vaccines and therapeutics pipeline, [D] recent developments and [E] an informed future outlook.
• Big Pharma Analysis: A comprehensive examination of various mRNA focused initiatives undertaken by major pharmaceutical companies. It includes a heat map representation that highlights mRNA therapeutics and vaccines under development (in partnership with core mRNA-focused entities), along with information on [A] funding amount raised, [B] partnership activity, and [C] diversity of product portfolio, as well as a spider web representation, comparing the initiatives of big pharmaceutical players on the basis of multiple relevant parameters.
• Start-up Health Indexing: An analysis of the startup companies engaged in this domain based on several relevant parameters, such as [A] number of candidates in discovery, [B] preclinical and clinical phases of development. In addition, it provides details on amount raised, number of investors and number of deals inked.
• Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various mRNA vaccines and therapeutics based on several relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] therapeutic area, [E] study design, [F] type of sponsor / collaborator, [G] leading industry players (in terms of number of trials conducted), [H] enrolled patient population and [I] geography.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2013, based on several relevant parameters, such as year of partnership, type of partnership, therapeutic area, most active players (in terms of number of deals inked) and regional distribution of partnership activity.
• Funding and Investment Analysis: A detailed evaluation of the investments made in the mRNA vaccines and therapeutics domain, encompassing seed financing, venture capital, IPOs, secondary offerings, debt, grants and other offerings based on several parameters, such as [A] year of funding, [B] type of funding, [C] amount invested, therapeutic area, most active players (in terms of number of funding instances and amount invested) and key investors (in terms of number of funding instances).
• Patent Analysis: Detailed analysis of various patents filed / granted related to mRNA therapeutics and vaccines several relevant parameters, such as [A] type of patent, [B] publication year, [C] geographical region, [D] CPC symbols, [E] leading industry players (in terms of the number of patents filed / granted) and [F] patent valuation.
• Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What amount has been invested in this domain?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Research Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Future Estimates
  • 3.2.2. Currency Coverage and Foreign Exchange Rate
    • 3.2.2.1. Major Currencies Affecting the Market
    • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
    • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
    • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
  • 3.2.3. Trade Policies
    • 3.2.3.1. Impact of Trade Barriers on the Market
    • 3.2.3.2. Strategies for Mitigating the

Risks associated with Trade Barriers

• 3.2.4. Recession
  • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
• 3.2.5. Inflation
  • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. mRNA Therapeutics
  • 5.2.1. Advantages of mRNA Therapeutics
  • 5.2.2. Key Applications of mRNA Therapeutics
• 5.3. mRNA Vaccines
  • 5.3.1. Advantages of mRNA Vaccines
  • 5.3.2. Key Applications of mRNA Vaccines
• 5.4. mRNA Delivery Routes
• 5.5. mRNA Delivery Strategies
• 5.6. Key Challenges Associated with mRNA Vaccine and Therapeutics
• 5.7. Future Perspectives

6. MARKET LANDSCAPE

• 6.1. Chapter Overview
• 6.2. mRNA Vaccine and Therapeutics: Overall Market Landscape
  • 6.2.1. Analysis by Phase of Development
  • 6.2.2. Analysis by Type of Drug Candidate
  • 6.2.3. Analysis by Therapeutic Area
  • 6.2.4. Analysis by Phase of Development and Therapeutic Area
  • 6.2.5. Analysis by Type of Delivery System
  • 6.2.6. Analysis by Type of Molecule Encoded
  • 6.2.7. Analysis by Route of Administration
  • 6.2.8. Analysis by Therapeutic Area and Route of Administration
  • 6.2.9. Analysis by Phase of Development, Therapeutic Area and Route of Administration

7. COMPETITIVE LANDSCAPE

• 7.1. Chapter Overview
• 7.2. mRNA Vaccine and Therapeutics: List of Developers
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Company Size
  • 7.2.3. Analysis by Location of Headquarters
  • 7.2.4. Key Players: Analysis by Number of Drug Candidates
  • 7.2.5. Key Players: Analysis by Phase of Development
  • 7.2.6. Key Players: Analysis by Therapeutic Area

8. COMPANY COMPETITIVENESS ANALYSIS

• 8.1. Chapter Overview
• 8.2. Assumptions and Parameters
• 8.3. Methodology
• 8.4. mRNA Vaccine and Therapeutics Developers: Company Competitiveness Analysis
  • 8.4.1. mRNA Vaccine and Therapeutics Developers based in North America

8. 4.2. mRNA Vaccine and Therapeutics Developers based in Europe

8. 4.3. mRNA Vaccine and Therapeutics Developers based in Asia-Pacific and Rest of the World

9. COMPANY PROFILES

• 9.1. Chapter Overview
• 9.2. Leading Companies in mRNA Vaccine and Therapeutics Market
  • 9.2.1. Arcturus Therapeutics
    • 9.2.1.1. Company Overview
    • 9.2.1.2. Financial Information
    • 9.2.1.3. Pipeline Overview
    • 9.2.1.4. Recent Developments and Future Outlook
  • 9.2.2. BioNTech
    • 9.2.2.1. Company Overview
    • 9.2.2.2. Financial Information
    • 9.2.2.3. Pipeline Overview
    • 9.2.2.4. Recent Developments and Future Outlook
  • 9.2.3. CureVac
    • 9.2.3.1. Company Overview
    • 9.2.3.2. Financial Information
    • 9.2.3.3. Pipeline Overview
    • 9.2.3.4. Recent Developments and Future Outlook
  • 9.2.4. Ethris
    • 9.2.4.1. Company Overview
    • 9.2.4.2. Pipeline Overview
    • 9.2.4.3. Recent Developments and Future Outlook
  • 9.2.5. Immorna
    • 9.2.5.1. Company Overview
    • 9.2.5.2. Pipeline Overview
    • 9.2.5.3. Recent Developments and Future Outlook
  • 9.2.6. Moderna
    • 9.2.6.1. Company Overview
    • 9.2.6.2. Financial Information
    • 9.2.6.3. Pipeline Overview
    • 9.2.6.4. Recent Developments and Future Outlook
  • 9.2.7. Providence Therapeutics
    • 9.2.7.1. Company Overview
    • 9.2.7.2. Pipeline Overview
    • 9.2.7.3. Recent Developments and Future Outlook
  • 9.2.8. Suzhou Abogen Biosciences
    • 9.2.8.1. Company Overview
    • 9.2.8.2. Pipeline Overview
    • 9.2.8.3. Recent Developments and Future Outlook
• 9.3. Other Leading Players in mRNA Vaccine and Therapeutics Market
  • 9.3.1. Gennova Biopharmaceuticals
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Pipeline Overview
  • 9.3.2. Innovac Therapeutics
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Pipeline Overview
  • 9.3.3. Kernal Biologics
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Pipeline Overview
  • 9.3.4. Pantherna Therapeutics
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Pipeline Overview
  • 9.3.5. pHion Therapeutics
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Pipeline Overview
  • 9.3.6. Recode Therapeutics
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Pipeline Overview
  • 9.3.7. Rejuvenation Technologies
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Pipeline Overview
  • 9.3.8. RNACure
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Pipeline Overview
  • 9.3.9. RNAimmune
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Pipeline Overview
  • 9.3.10. Strand Therapeutics
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Pipeline Overview
  • 9.3.11. Turn Biotechnologies
    • 9.3.11.1. Company Overview
    • 9.3.11.3. Pipeline Overview
  • 9.3.12. Walvax Biotechnology
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Pipeline Overview
  • 9.3.13. Ziphius Vaccines
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Pipeline Overview

10. BIG PHARMA INITIATIVES

• 10.1. Chapter Overview
• 10.2. Scope and Methodology
• 10.3. mRNA Related Initiatives of Big Pharmaceutical Players
  • 10.3.1. Analysis by Portfolio Diversity
  • 10.3.2. Analysis by Phase of Development
  • 10.3.3. Analysis by Target Therapeutic Area
• 10.4. Benchmarking Analysis: Big Pharma Players
  • 10.4.1. Spider Web Analysis: Amgen
  • 10.4.2. Spider Web Analysis: AstraZeneca
  • 10.4.3. Spider Web Analysis: Bayer
  • 10.4.4. Spider Web Analysis: BioNTech
  • 10.4.5. Spider Web Analysis: Eli Lilly
  • 10.4.6. Spider Web Analysis: Gilead Sciences
  • 10.4.7. Spider Web Analysis: GlaxoSmithKline
  • 10.4.8. Spider Web Analysis: Merck
  • 10.4.9. Spider Web Analysis: Moderna
  • 10.4.10. Spider Web Analysis: Novartis
  • 10.4.11. Spider Web Analysis: Novo Nordisk
  • 10.4.12. Spider Web Analysis: Pfizer
  • 10.4.13. Spider Web Analysis: Roche
  • 10.4.14. Spider Web Analysis: Sanofi
  • 10.4.15. Spider Web Analysis: Takeda
• 10.5. Concluding Remarks

11. START-UP HEALTH INDEXING

• 11.1. Chapter Overview
• 11.2. Start-ups focused on mRNA Vaccine and Therapeutics
  • 11.2.1. Analysis by Location of Headquarters
• 11.3. Benchmarking of Start-ups
• 11.4. Start-up Health Indexing
  • 11.4.1. Analysis by Supplier Strength
  • 11.4.2. Analysis by Pipeline Maturity
  • 11.4.3. Analysis by Pipeline Strength
  • 11.4.4. Analysis by Financial Investments
  • 11.4.5. Analysis by Partnership Activity
  • 11.4.6. Start-ups Health Indexing: Roots Analysis Perspective

12. CLINICAL TRIAL ANALYSIS

• 12.1. Chapter Overview
• 12.2. Scope and Methodology
• 12.3. mRNA Vaccine and Therapeutics: Clinical Trial Analysis
  • 12.3.1. Analysis by Trial Registration Year
  • 12.3.2. Analysis by Trial Status
  • 12.3.3. Analysis by Trial Phase
  • 12.3.4. Analysis by Trial Registration Year and Trial Status
  • 12.3.5. Analysis by Trial Registration Year and Trial Phase
  • 12.3.6. Analysis by Trial Status and Trial Phase
  • 12.3.7. Analysis of Enrolled Patient Population by Trial Registration Year
  • 12.3.8. Analysis by Study Design
  • 12.3.9. Analysis by Type of Sponsor / Collaborator
  • 12.3.10. Most Active Players: Analysis by Number of Registered Trials
  • 12.3.11. Analysis by Therapeutic Area
  • 12.3.12. Analysis by Number of Registered Trials and Geography
  • 12.3.13. Analysis by Number of Registered Trials, Trial Status and Geography
  • 12.3.14. Analysis of Enrolled Patient Population by Geography

13. PARTNERSHIPS AND COLLABORATIONS

• 13.1. Chapter Overview
• 13.2. Partnership Models
• 13.3. mRNA Vaccine and Therapeutics: Partnerships and Collaborations
  • 13.3.1. Analysis by Year of Partnership
  • 13.3.2. Analysis by Type of Partnership
  • 13.3.3. Analysis by Year and Type of Partnership
  • 13.3.4. Analysis by Therapeutic Area
  • 13.3.5. Analysis by Type of Partnership and Therapeutic Area
  • 13.3.6. Most Active Players: Analysis by Number of Partnerships
  • 13.3.7. Analysis by Geography
    • 13.3.7.1. Intercontinental and Intracontinental Agreements
    • 13.3.7.2. Local and International Agreements

14. FUNDING AND INVESTMENT ANALYSIS

• 14.1. Chapter Overview
• 14.2. Types of Funding
• 14.3. mRNA Vaccine and Therapeutics: Funding and Investments
  • 14.3.1. Analysis by Year of Funding
  • 14.3.2. Analysis by Amount Invested
  • 14.3.3. Analysis by Type of Funding
  • 14.3.4. Analysis by Year and Type of Funding
  • 14.3.5. Analysis of Funding Instances and Amount Invested by Therapeutic Area
  • 14.3.6. Analysis by Geography
  • 14.3.7. Most Active Players: Analysis by Number of Funding Instances
  • 14.3.8. Most Active Players: Analysis by Total Amount Raised
  • 14.3.9. Most Active Investors: Analysis by Number of Funding Instances
  • 14.3.10. Analysis of Amount Invested by Year and Type of Funding

15. PATENT ANALYSIS

• 15.1. Chapter Overview
• 15.2. Scope and Methodology
• 15.3. mRNA Vaccine and Therapeutics: Patent Analysis
  • 15.3.1. Analysis by Type of Patent
  • 15.3.2. Analysis by Patent Publication Year
  • 15.3.3. Analysis of Granted Patents by Publication Year
  • 15.3.4. Analysis of Patent Applications by Publication Year
  • 15.3.5. Analysis of Granted Patents and Patent Applications by Publication Year
  • 15.3.6. Analysis by Publication Year and Type of Applicant
  • 15.3.7. Analysis by Patent Jurisdiction
  • 15.3.8. Analysis by Patent Age
  • 15.3.9. Analysis by CPC Symbols
  • 15.3.10. Leading Players: Analysis by Number of Patents
  • 15.3.11. Leading Inventors: Analysis by Number of Patents
• 15.4. Patent Benchmarking Analysis
  • 15.4.1. Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
• 15.5. mRNA Vaccine and Therapeutics: Patent Valuation Analysis

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 16.1. Chapter Overview
• 16.2. Market Drivers
• 16.3. Market Restraints
• 16.4. Market Opportunities
• 16.5. Market Challenges
• 16.6. Conclusion

17. GLOBAL mRNA VACCINE AND THERAPEUTICS MARKET

• 17.1. Chapter Overview
• 17.2. Assumptions and Methodology
• 17.3. Global mRNA Vaccine and Therapeutics Market, till 2035
  • 17.3.1. Scenario Analysis
    • 17.3.1.1. Conservative Scenario
    • 17.3.1.2. Optimistic Scenario
• 17.4. Key Market Segmentations

18. mRNA VACCINE AND THERAPEUTICS MARKET, BY APPLICATION AREA

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. mRNA Vaccine and Therapeutics Market: Distribution by Application Area, 2024, 2028 and 2035
  • 18.3.1. mRNA Vaccine and Therapeutics Market for COVID-19, till 2035
  • 18.3.2. mRNA Vaccine and Therapeutics Market for Other Indications, till 2035
• 18.4. Data Triangulation and Validation

19. mRNA VACCINE AND THERAPEUTICS MARKET, BY TARGET DISEASE INDICATION

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. mRNA Vaccine and Therapeutics Market: Distribution by Target Disease Indication, 2026, 2030 and 2035
  • 19.3.1. mRNA Vaccine and Therapeutics Market for Influenza, till 2035
  • 19.3.2. mRNA Vaccine and Therapeutics Market for Respiratory Syncytial Virus Infection, till 2035
  • 19.3.3. mRNA Vaccine and Therapeutics Market for Cytomegalovirus Disease, till 2035
• 19.4. Data Triangulation and Validation

20. mRNA VACCINE AND THERAPEUTICS MARKET, BY GEOGRAPHICAL REGIONS

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. mRNA Vaccine and Therapeutics Market: Distribution by Geographical Regions, 2024, 2028 and 2035
  • 20.3.1. mRNA Vaccine and Therapeutics Market in North America, till 2035
    • 20.3.1.1. mRNA Vaccine and Therapeutics Market in the US, till 2035
    • 20.3.1.2. mRNA Vaccine and Therapeutics Market in Canada, till 2035
  • 20.3.2. mRNA Vaccine and Therapeutics Market in Europe, till 2035
    • 20.3.2.1. mRNA Vaccine and Therapeutics Market in Germany, till 2035
    • 20.3.2.2. mRNA Vaccine and Therapeutics Market in the UK, till 2035
    • 20.3.2.3. mRNA Vaccine and Therapeutics Market in France, till 2035
    • 20.3.2.4. mRNA Vaccine and Therapeutics Market in Italy, till 2035
    • 20.3.2.5. mRNA Vaccine and Therapeutics Market in Spain, till 2035
    • 20.3.2.6. mRNA Vaccine and Therapeutics Market in Belgium, till 2035
  • 20.3.3. mRNA Vaccine and Therapeutics Market in Aisa-Pacific, till 2035
    • 20.3.3.1. mRNA Vaccine and Therapeutics Market in China, till 2035
    • 20.3.3.2. mRNA Vaccine and Therapeutics Market in India, till 2035
    • 20.3.3.3. mRNA Vaccine and Therapeutics Market in Japan, till 2035
    • 20.3.3.4. mRNA Vaccine and Therapeutics Market in Philippines, till 2035
    • 20.3.3.5. mRNA Vaccine and Therapeutics Market in Australia, till 2035
  • 20.3.4. mRNA Vaccine and Therapeutics Market in Latin America, till 2035
    • 20.3.4.1. mRNA Vaccine and Therapeutics Market in Brazil, till 2035
  • 20.3.5. mRNA Vaccine and Therapeutics Market in Rest of the World, till 2035
• 20.4. Data Triangulation and Validation

21. CONCLUSION

22. EXECUTIVE INSIGHTS

• 22.1. Chapter Overview
• 22.2. Canvax
  • 22.2.1. Company Snapshot
  • 22.2.2. Interview Transcript: Business Development Manager
• 22.3. eTheRNA
  • 22.3.1. Company Snapshot
  • 22.3.2. Interview Transcript: Senior Director, Business Development
• 22.4. GC Biopharma
  • 22.4.1. Company Snapshot
  • 22.4.2. Interview Transcript: Team Leader

23. APPENDIX 1: TABULATED DATA

24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료